The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
BUSINESS
Sumitomo Notches Record Profit on Strong North America Growth
Sumitomo Pharma logged record sales and profits for the fiscal year ended March 2026, buoyed by strong growth of its three core products in North America, cost cuts through business restructuring, and gains related to the transfer of its Asian…
To read the full story
Related Article
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- Sumitomo Flags Diabetes Pipeline Gap as Key Strategic Issue: CEO
February 2, 2026
- Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
- Sumitomo Ups FY2025 Forecast on North America-Driven Profit Growth
November 4, 2025
- Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
August 8, 2025
- Sumitomo Charts Revival Plan, Eyes 250 Billion Yen with 3 Key Meds by FY2027
May 14, 2025
BUSINESS
- Kissei Cuts H1 Profit Outlook on Tavneos Approval Revocation Risk
October 29, 2026
- Nxera Licenses Fabry Disease Drug from Idorsia
October 29, 2026
- Novo Nordisk Hints at GLP-1 Supply Restrictions to Curb Inappropriate Use
October 29, 2026
- J-TEC, Maruho to Co-Promote Jacemin from April
October 29, 2026
- KM Biologics to Supply Mpox Vaccine to WHO-Led Vaccine Stockpile
October 29, 2026
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…